SOLENO THERAPEUT. DL-001 Total Liabilities
SOLENO THERAPEUT. DL-001 total liabilities. Based on the latest financial reports, SOLENO THERAPEUT. DL-001 (6XC) has total liabilities worth €113.72 Million EUR (≈ $132.94 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SOLENO THERAPEUT. DL-001 (6XC) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SOLENO THERAPEUT. DL-001 (2021–2025)
Total liabilities of SOLENO THERAPEUT. DL-001 from 2021 to 2025. This chart illustrates how SOLENO THERAPEUT. DL-001's total liabilities have evolved over time, based on quarterly financial data. Explore SOLENO THERAPEUT. DL-001 long-term investment allocation to see how much of total assets are deployed in long-term investments.
SOLENO THERAPEUT. DL-001 Competitors by Total Liabilities
The table below lists competitors of SOLENO THERAPEUT. DL-001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ternium Argentina SA
BA:TXAR
|
Argentina | AR$783.28 Billion |
|
Enerflex Ltd.
TO:EFX
|
Canada | CA$2.37 Billion |
|
TAV HAVALIMAN.HLDG ADR/4
F:5THA
|
Germany | €3.31 Billion |
|
Hangzhou Cable
SHG:603618
|
China | CN¥7.89 Billion |
|
Allos S.A.
SA:ALOS3
|
Brazil | R$12.76 Billion |
|
Regional S.A.B. de C.V
MX:RA
|
Mexico | MX$255.48 Billion |
|
KEPCO Engineering & Construction
KO:052690
|
Korea | ₩239.41 Billion |
|
Calix Inc
NYSE:CALX
|
USA | $213.43 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down SOLENO THERAPEUT. DL-001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SOLENO THERAPEUT. DL-001 asset portfolio.
Liquidity & Leverage Metrics
SOLENO THERAPEUT. DL-001 Total Liabilities Ratios Explained
SOLENO THERAPEUT. DL-001 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SOLENO THERAPEUT. DL-001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SOLENO THERAPEUT. DL-001 (2021–2025)
The table below shows the annual total liabilities of SOLENO THERAPEUT. DL-001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €113.72 Million ≈ $132.94 Million |
+32.44% |
| 2024-12-31 | €85.86 Million ≈ $100.38 Million |
+270.34% |
| 2023-12-31 | €23.18 Million ≈ $27.10 Million |
+43.56% |
| 2022-12-31 | €16.15 Million ≈ $18.88 Million |
-9.07% |
| 2021-12-31 | €17.76 Million ≈ $20.76 Million |
-- |
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more